Thus, given the accumulating evidence regarding the involvement of the TGF-β signaling pathway in ALS disease progression, it has been recently proposed that decreased levels of TGF-β in the early stages of ALS may diminish its neuroprotective activity, increasing the glutamate-induced excitotoxicity. The gene discussed is TGFB1; the disease is amyotrophic lateral sclerosis.